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Abstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibi-
tor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an 
unprecedented eight years. In the wake of this rapid approval arose a large number of ques-
tions about its mechanism of action and toxicity as well as its ultimate role in the treatment 
of this disease. In this article, we briefly review the preclinical and clinical development 
of the drug as the underpinning for a systematic review of the large number of clinical tri-
als that are beginning to shed some light on the full therapeutic potential of bortezomib in 
myeloma. We conclude with our current understanding of the mechanism of action of this 
agent and a discussion of the novel proteasome inhibitors under development, as it will 
be progress in these areas that will ultimately determine the true potential of proteasome 
inhibition in myeloma.
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The proteasome
The proteasome is a large, hollow cylindrical multi-enzymatic complex that is 
present in both the cytoplasm and the nucleus of all eukaryotic cells. It is necessary 
for the degradation of intracellular proteins in eukaryotic cells whereas extracellular/
transmembrane proteins are typically degraded by the aggresome/lysosomal pathway.1 
The proteins degraded by the former pathway are involved in signal transduction 
pathways that regulate cell growth and proliferation including: cell-cycle-regulatory 
proteins (cyclins A, B, D, and E; p21 and p27), the tumor suppressor p53, NF-κB, 
and adhesion molecules.4
The formation of the 26S proteasome occurs in an ATP dependent fashion, when a 
20S catalytic core is capped by a 19S regulatory subunit at both ends (see Figure 1A).1 
The lysine residues of those proteins targeted for degradation are covalently modified 
with a polyubquitin protein chain, with each ubiquitin tag consisting of a 76 amino acid 
polypeptide. The ubiquitin chain is recognized by the lid-like structure of the19S subunit 
and then removed. The target protein is then denatured in an energy dependent manner 
by the 6 ATPases at the base of the 19S subunit and threaded into the center of the 20S   
subunit.2
As shown in Figure 1B, the 20S subunit is itself comprised of four rings, 2 α and 2 
β subunits. Within the channel at the center, threonine residues of the indicated β units 
wield catalytic activity comparable to three enzymes: chymotrypsin (β5), trypsin (β2), and 
post-glutamyl peptide hydrolase (β1).
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the ubiquitin–proteasome pathway. A team of enzymologists 
created the first inhibitors of the proteasome: peptide aldehyde 
analogs of the proteasome’s chymotrypsin-like substrates. 
Chemists then created a dipeptide boronic acid analog 
that would eventually come to be known as bortezomib 
(Figure 2).3
When applied to the National Cancer Institute’s 60-cell 
line screen, bortezomib demonstrated potent growth inhi-
bition against a broad range of tumor types.5 Importantly, 
confirmation was also obtained that the intended biologic 
target was being inhibited. Additional studies with human 
myeloma cell lines and freshly isolated from myeloma 
patients confirmed that bortezomib not only inhibited tumor 
proliferation but also induced apoptosis and overcame drug 
resistance.6
The growth inhibition of bortezomib was extended to 
the in vivo setting using a human plasmacytoma xenograft 
mouse model. Relative to controls, bortezomib treatment 
resulted in improved overall survival.7 A fluorogenic 
pharamacodynamic assay was developed to measure 
the relative chymotryptic and tryptic activities of the 
proteasome in peripheral blood mononuclear cells.8 This 
assay showed that bortezomib-mediated inhibition of the 
chymotrypsin-like activity of the 26S mammalian protea-
some (Figure 1B) was dose-dependent and reversible,7 
thus helping guide dosing and optimize dose escalation 
in phase I studies.
Clinical development  
of bortezomib – relapsed/ 
refractory multiple myeloma
In a phase I trial among patients with advanced hematologi-
cal malignancies, bortezomib was noted to have activity in 
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Figure 1A Structure of 26S proteasome: the 26S proteasome is formed when 
the 20S catalytic core is capped by 19S regulatory subunits at both ends in an ATP 
dependent fashion.
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Figure 1B Cross section of the β ring of the 20S subunit of the proteasome: 
the post-glutamyl, tryptic, and chymotryptic sites are comprised of the threonine 
residues of the β1,  β2, and β5 subunits respectively. Bortezomib inhibits the 
chymotryptic site.
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Figure 2 Chemical structure of bortezomib.
Preclinical development 
of bortezomib
In 1993, the company Myogenics was founded by Alfred 
Goldberg to decrease muscle wasting/cachexia by inhibiting Biologics:   Targets & Therapy 2010:4 275
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patients with refractory myeloma; among nine patients with 
multiple myeloma antitumor activity was noted in almost all 
patients including 1 patient achieving a complete response.4 
A subsequent, large, multicenter phase II trial involving 
202 patients with relapsed, refractory myeloma yielded a 
35% overall response rate which was comprised of a 4% 
complete remission (CR), 6% near CR, 18% partial remission 
(PR), and 7% minimal response (MR).9 It was on the basis 
of this trial in large part, that bortezomib was approved by 
the United States Food and Drug Administration (FDA) in 
2003, thus resulting in a remarkably short 8 years from drug 
discovery to FDA approval.
The phase III Assessment of Proteasome Inhibition for 
Extending Remissions (APEX) study compared bortezomib 
(1.3 mg/m2 on days 1,4, 8, and 11 by intravenous push for 
eight 3-week cycles) to high dose dexamethasone (40 mg 
days 1–4, 9–12, and 17–20 orally for four 5-week cycles 
and then days 1–4 for five 4-week cycles) in 669 patients 
with relapsed multiple myeloma. The study was halted on 
interim analysis because bortezomib treatment resulted in 
higher response rates (38 vs 18%), longer time to progres-
sion (6.22 months vs 3.49 months), and improved overall 
survival. The median time to response was 43 days in 
both groups.10 In an updated analysis, based on a median 
follow up of 22 months, the median overall survival was 
29.8 vs 23.7 months (P = 0.0272) despite a 62% crossover 
rate from dexamethasone to boretzomib.11 As shown in 
Figure 3, a comparison of the Grade 3/4 adverse events in 
each arm reveals that bortezomib treatment is associated with 
an increased incidence of thrombocytopenia, neutropenia, 
peripheral neuropathy, and diarrhea.10 The thrombocytopenia 
and neuropathy are discussed in further detail below. Despite 
these toxicities, a prospective comparsion of health-related 
quality of life found improved outcomes with bortezomib.12 
Of note, subgroup analysis has also found no difference in 
safety or efficacy in patients with varying degrees of renal 
insufficiency.13
Bortezomib therapy also appears to have beneficial 
effects on the bone. When alkaline phosphatase levels were 
compared with responders and nonresponders in the APEX 
study, the most powerful predictor of a response was a 25% 
increase in alkaline phosphatase at week 6 (P  0.0001) 
(Figure 4).14 Laboratory work has confirmed the ability 
of bortezomib to not only inhibit osteclast mediated bone 
destruction, but also directly induce bone formation.15,16 
Interestingly, as shown in Figure 4, the increase in alka-
line phosphatase was not observed on the dexamethasone 
arm, even in the responders.14 This increase has also been 
recently found to be associated with improved time to pro-
gression.17
As the safety and efficacy results for bortezomib mono-
therapy were accumulating, combination therapy was being 
explored in the preclinical setting. Hideshima et al found 
that the growth inhibitory effects of bortezomib and dexa-
methasone on a myeloma cell line were additive (Figure 5A).6 
Ma et al found that the addition of a noncytotoxic dose of 
bortezomib to chemotherapeutic agents could increase the 
sensitivity of chemoresistant myeloma cells by 100,000 to 
1,000,000-fold without affecting normal hematopoietic cells 
(Figure 5B).18
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Figure 3 Grade 3/4 adverse events of bortezomib and dexamethasone in the APeX trial.Biologics:   Targets & Therapy 2010:4 276
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The largest published phase III clinical trial combining 
bortezomib with another chemotherapeutic agent randomized 
646 myeloma patients with 2 or more lines of prior therapy 
to receive either the standard dose/schedule of bortezomib 
alone or with liposomal doxorubicin (PLD) on Day 4. The 
combination therapy was associated with a higher incidence 
of grade 3/4 events 80 vs 64% (due to myelosuppression, 
constitutional and gastrointestinal symptoms, and hand 
foot syndrome). There was also no significant difference 
in response rates. However, the time to progression (9.3 vs 
6.5 months, P = 0.000004) and overall survival at 15 months 
(76% vs 65%, P = 0.03) both favored bortezomib with PLD.19 
This steroid sparing regimen is an excellent treatment option 
especially for those patients intolerant of steroids due to 
psychosis or brittle diabetes.
The proteasome inhibitor bortezomib has now been 
studied in combination with each of the three other classes 
of drugs with activity in myeloma: steroids, immunomodu-
latory agents (IMids), and conventional chemotherapeutics
(anthracyclines and alkylating agents). For those phase I/II 
studies with 30 or more evaluable patients, summaries of the 
recent response data of doublet (Table 1), triplet (Table 2), 
and multiagent (Table 3) permutations of the four classes 
of drugs in relapsed/refractory myeloma are shown in the 
indicated tables.
Bortezomib in previously untreated 
multiple myeloma
The only published phase III study of bortezomib in untreated 
myeloma is the Velcade as Initial Standard Therapy in 
Multiple Myeloma: Assessment with Melphalan Prednisone 
(VISTA) study. In this study, 682 nontransplant eligible 
patients with untreated myeloma were randomized to receive 
either melphalan and prednisone alone (MP) or with bortezo-
mib (VMP) at the doses and schedule shown in Figure 6.
Overall response rate for VMP was 71% vs 35% for MP 
with a very impressive CR rate of 30% vs 4% (P  0.001 for 
both comparisons). Of note, a 30% CR rate compares very 
favorably to the CR rates obtained for patients who receive 
high dose melphalan chemotherapy with autologous stem cell 
rescue (for which none of the patients in the VISTA study 
were eligible). With a median follow up of 16.3 months, the 
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Figure 4 Median levels of alkaline phosphatase levels of patients with multiple myeloma who responded to treatment with bortezomib and dexamethasone in the APeX trial. 
reproduced with permission from Zangari M, esseltine D, Lee CK, et al. response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. 
Br J Haematol. 2005;131(1):71–73.14 Copyright © 2005 John wiley and Sons.
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Figure 5A Dexamethasone sensitive myeloma cells (MM.1S) cultured with 0.001 to 
0.625 × 10-6 M. Dexamethasone in control media () and with bortezomib 0.0025   
(    ) or 0.005 (■) × 10-6 M. reproduced with permission from Hideshima T, richardson P, 
Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, 
and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7): 
3071–3076.6 Copyright © 2001 American Association for Cancer research.Biologics:   Targets & Therapy 2010:4 277
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Figure 5B The addition of bortezomib to chemotherapeutic agents results in synergistic cytotoxicity in multiple myeloma cells: A) Melphalan-resistant cell line (rPMi8228/Lr) 
treated for 24 hours with varying concentrations of melphalan alone or in combination with a noncytotoxic dose of bortezomib; B) Doxorubicin-resistant cell line (U266/dox4) 
treated for 24 hours with varying concentrations of doxorubicin alone or in combination with a noncytotoxic dose of bortezomib. C) Fresh myeloma cells treated with varying 
concentrations of melphalan alone or in combination with a noncytotoxic dose of bortezomib. reproduced with permission from Ma MH,  Yang HH, Parker K, et al. The proteasome 
inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3):1136–1144.18 Copyright © 2003 American 
Association for Cancer research.
hazard ratio for overall survival for the VMP group was 0.61 
(P = 0.008).34
All of the following efficacy outcomes were also 
significantly better for the VMP group relative to MP: 
median time to first response (1.4 vs 4.2 months), duration 
of response (20 vs 13 months), and treatment-free interval 
(17 months vs 9 months). The improved outcomes were seen 
in all subgroups, including age 75, creatinine clearance 60, 
and high risk cytogenetics (translocation (t) (4;14), t(14,16), or 
chromosome 17 deletion).34 Of note, the lack of effect of high 
risk cytogenetics on efficacy with borezomib-based regimens 
has been a consistent finding across all front line studies.34–37Biologics:   Targets & Therapy 2010:4 278
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Toxicities  Grade 3 that were higher in the VMP 
arm included peripheral neuropathy (14 vs 0%), nausea/
vomiting/diarrhea, fatigue/asthenia, and zoster. Herpes 
zoster was observed in 14% of VMP patients vs 4% in MP, 
but among patients receiving antiviral prophylaxis, the rate 
was 3%.34 
Of note, a recent analysis of varicella zoster virus (VZV) 
reactivation in the APEX study also found a significantly 
increased incidence in patients receiving bortezomib rela-
tive to dexamethasone 13% vs 5%, P = 0.0002.38 Antiviral 
prophylaxis is therefore recommended for all myeloma 
Table 1 Clinical trials of bortezomib in doublet-drug combination 
regimens
Study Phase Regimen n CR/nCR ORR
Berenson et al20 i/ii vel/Mel 46 15% 70%
Popat et al21 i/ii vel/Mel ± Dex 53 23% 68%
Pineda-roman et al22 i/ii vT ± Dex 85 22% 63%
Abbreviations: n, number of evaluable patients; Cr, complete remission; nCr, 
near complete remission;  Orr, overall response rate;   vel/Mel, velcade, melphalan; 
vT, velcade, thalidomide.
Table 2 Clinical trials of bortezomib in triplet-drug combination 
regimens
Study Phase Regimen n/N CR/nCR ORR
reece et al23 i/ii vCP 37/37 27% 68%
Kropff et al24 ii vCD 50/54 16% Cr 82%
Hajek et al25 ii 39/40 – 51%
Lee et al26 ii PAD→TD 30/39 70% 90%
Palumbo et al27 PAD 64/64 25% 67%
richardson et al28 ii vrD 62/24 21% 84% (Mr)
Poensich et al29 ii vBP 46/46 15% 61%
Abbreviations: n/N, number of evaluable patients/total number of enrolled patients; 
vCP, bortezomib, cyclophosphamide, prednisone; vCD, bortezomib, cyclophospha-
mide, dex; PAD, bortezomib, adriamycin, dex; TD, thalidomide, dex; vrD: bortezomib, 
lenalidomide, dex; vBP, bortezomib, bendamustine, prednisone. 
patients receiving bortezomib based regimens. A variety 
of agents and regimens have been used including acyclovir 
400 mg daily, valacyclovir 250 or 500 mg daily, famciclovir 
500 mg daily.39,40 Doses should be decreased in the setting 
of renal insufficiency as the metabolites of these drugs 
can accumulate and cause profound neuropsychiatric 
changes.41,42 Finally, the varicella vaccine, which contains 
live attenuated virus, is not licensed for use in patients 
with neoplasms affecting the bone marrow or lymphatic 
systems.43
Additional follow up data presented recently indicated 
that despite the fact that 43% of MP patients subsequently 
received bortezomib upon progression, intention to treat 
analysis still demonstrated increased overall survival for 
the VMP group. Moreover, there was no difference in 
response to IMiD-based second line treatments between 
the two groups.44 The results of the VISTA study therefore 
demonstrate clearly improved efficacy with VMP without 
any adverse long term consequences of upfront bortezomib 
based regimens.
There are also several large phase III studies ongoing 
evaluating the use of bortezomib as induction therapy 
prior to stem cell transplantation (see Table 4). The Fran-
chophone Myeloma Intergroup (IFM) 2005-01 study 
randomized 482 patients to receive either bortezomib-
dexamethasone (Vel-Dex) or the traditional VAD. Of the 
442 evaluable patients, the CR rates were 10% vs 3%, CR 
+ near CR 19% vs 8%, and  PR 83 vs 66% without any 
impairment in stem cell harvest. Moreover, the higher 
quality of responses persisted after the first melphalan 
200 mg/m2 followed by autologous stem cell rescue, with 
CR/near CR rates of 40 vs 22%, P = 0.0001.36 Preliminary 
data from two other phase III studies comparing bortezo-
mib in combination with doxorubicin and dexamethasone 
(PAD) to traditional VAD37 and bortezomib, thalidomide, 
and dexamethasone (VTD) to TD35 also found improved 
CR/nCR rates (23% vs 9%, P  0.015 and 55% vs 32%, 
P  0.001 respectively) after autologous stem cell trans-
plantation.
These improvements in CR rates after transplant with 
bortezomib based induction therapies have clinical sig-
nificance. Two large published phase III studies compar-
ing single vs tandem autologous stem cell transplants in 
myeloma found that patients who did not achieve a CR/near 
CR after the first autologus stem cell transplant were the 
ones that could benefit from a second SCT.48,49 Therefore, 
the higher CR rates being obtained with novel induction 
regimens may obviate the need for a second autologous 
Table 3 Clinical trials of bortezomib in multiple drug combination 
regimens
Study Phase Regimen n Cr/nCR ORR
Palumbo et al30 i/ii vMPT 30/30 44%a 67%
Terpos et al31 ii vMDT 62a – 66%
Ciolli et al32 ii vTDD 42/42 52% 74%
Kim et al33 ii vCTD 56/35 53% Cr 92%
anumber of evaluable patients unknown.
Abbreviations: n, number of evaluable patients; Cr, complete remission; nCr, near 
complete remission; Orr, overall response rate;   vMPT, bortezomib, melphalan, predni-
sone, thalidomide;  vMDT, bortezomib, melphalan, dex, thalidomide;  vTDD, bortezomib, 
thalidomide, dex, liposomal doxorubicin;   vCTD, bortezomib, cyclophosphamide, 
thalidomide, dex.Biologics:   Targets & Therapy 2010:4 279
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transplant – with its attendant mortality, morbidity, and 
cost.
While the details of the various bortezomib based front 
line regimens are beyond the scope of this review, a summary 
of the responses noted to date are shown in Table 5. With the 
understanding that response rates in single/few institution 
phase II studies are typically higher than those obtained in 
phase III multi-institutional settings, a regimen that stands 
out is bortezomib, lenalidomide, and dexamethasone (VRD). 
With 65 evaluable patients, the combination of bortezo-
mib, lenalidomide, and dexamethasone resulted in a 100% 
response rate and a 38% CR/nCR rate.50 A caveat of course, 
is that lenalidomide based induction regimens often result 
in inadequate stem cell harvests with granulocyte colony 
stimulating factor (GCSF) mobilization and therefore 
require cyclophosphamide or the recently FDA-approved 
CXCR inhibitor, plerixafor, to ensure adequate stem cell 
harvests.
Mechanism of action of bortezomib
While rational drug design and pharmacodynamic assays 
identified and confirmed the proteasome as the biologic 
target, without an understanding of the exact mechanism of 
action, the full therapeutic potential of proteasome inhibition 
cannot be realized. Research has focused on three possible 
themes that will be discussed below: the transcription factor 
NF-κB, the interaction of the pro-apoptotic factor NOXA 
and the c-myc oncogene, and finally, the transcription factor 
x-box binding protein 1 (XBP-1) and the unfolded protein 
response.
Initial focus was on the impact of bortezomib on NF-κB, 
which promotes tumor cell survival and proliferation. The 
inhibitor protein I-κB binds NF-κB in the cytoplasm, thereby 
rendering NF-κB inactive. A variety of cytokines and other 
cellular stimuli result in the phosphorylation and ubiquitina-
tion of I-κB by E3 ligase, thus targeting it for proteasome 
mediated degradation (Figure 7).2
Bortezomib, by blocking the latter process, results in 
increased availability of I-κB to inhibit NF-κB, resulting 
in the inhibition of tumor cell growth. Gene expression 
profiling studies in patients with myeloma who responded 
to bortezomib treatment also highlighted pathways such as 
NF-κB activity and cell adhesion, thereby confirming pre-
clinical studies.69
Additional work by Hideshima et al revealed that bort-
ezomib activation seemed to be dependent on the activation 
of c-Jun NH2-terminal kinase (JNK) and subsequently 
caspases-8 and caspase-3 that elicit DNA damage and 
apoptosis. In parallel, bortezomib was noted to be associated 
with the up-regulation of p53.70 While these inital studies 
shed some light on the mechanism of action, it is unclear 
if the changes observed in NF-κB and JNK are a cause or 
the result of the death process. Indeed, more recent studies 
suggest the antimyeloma activity of proteasome inhibition 
is actually p53 independent.71
When myeloma cell lines are exposed to bortezomib, the 
proapoptotic factor NOXA is induced in a concentration depen-
dent manner accompanied by the activation of caspases. NOXA 
is also induced by p53 and other transcriptional factors such 
as hypoxia-inducible factor 1 (HIF-1) and E2F-1, consistent 
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Bortezomib 1.3 mg/m2 IV: days 1, 4, 8, 11, 22, 25, 29, 32
Bortezomib 1.3 mg/m2 IV: days 1, 8, 22, 29
Melphalan 9 mg/m2 and prednisone 60 mg/m2 days 1–4
Melphalan 9 mg/m2 and prednisone 60 mg/m2 days 1–4
9 × 6-week cycles (54 weeks) in both arms 
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Figure 6 Chemotherapy schedule of bortezomib, melphalan, and prednisone (vMP) 
and melphalan and prednisone (MP) in the viSTA trial.
Abbreviations: vMP, velcade, melphalan, prednisone; MP, melphalan, prednisone.
Table 4 Summary of phase iii trials in previously untreated MM
Trial Regimen N/N† CR/nCR VGPR PR ORR
iFM 2005-01: Harousseau et al36 vel/Dex (vs vAD) 424/482 19% (vs 8%) 24% 43% 83%
HOvON-655/GMMG-H4: Sonneveld et al37 PAD (vs vAD) 300/300 23% (vs 9%) 37% – 83%
GiMeMA: Cavo et al35 vTD (vs TD) 460/474 55% (vs 32%) 30% 32% 94%
PeTHeMA/GeM: rosinol et al47 vTD vs (TD vs vBMCP/vBAD/vel) 183/190 41% (vs 12% vs 28%) – 39% 80%
viSTA: San Miguel et al34,44 vMP (vs MP) 668/682 30% Cr (vs 4%) N/A 40% 71%
GeM05MAS65: Mateos et al45 vMPT (vs vTP) 206/260 41% (vs 37%) – 40% 81%
GiMeMA: Palumbo et al46 vMPT (vs vMP) 354/393 39% Cr (vs 21%) 16% 32% 87%
Abbreviations:   vGPr, very good partial remission;   vMP, bortezomib, melphalan, prednisone; MP, melphalan, predisone;   vMPT, bortezomib, melphalan, prednisone, thalidomide; 
vTP, bortezomib, thalidomide, prednisone;   vAD, vincristine, adriamycin, doxorubicin; PAD, bortezomib, doxorubicin, dexamethasone;   vTD, velcade, thalidomide, dexamethasone; 
TD, thalidomide, dexamethasone;   vBMCP, BCNU, vincristine, melphalan, prednisone; vBAD, vincristine, BCNU, doxorubicin, dexamethasone.Biologics:   Targets & Therapy 2010:4 280
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Table 5 Phase i/ii and ii combination trials in untreated myeloma
Trial Regimen n/N CR/nCR VGPR PR ORR
Harousseau et al51 vel/Dex 48/52 21% Cr 10% 35% 67%
Corso et al52 54/54 50% 20% 16% 86%
rosinol et al53 vel alternating with Dex 40/40 13% Cr 10% 43% 65%
Jagannath et al54 vel ± Dex 49/49 18% 20% 49% 88%
Orlowski et al55 vel ± PLD 29/63 28% – 52% 79%
Jakubowiak et al56 vDD 30/30 40% Cr 23% 30% 93%
Palumbo et al57 102/102 13% Cr 47% 36% 96%
Belch et al58 50/50 18% – 60% 78%
Landau et al59 vDD→TD 31/31 29% 10% 42% 81%
wang et al60 vTD 38/38 16% – 71% 87%
Kaufman et al61 34/34 27% Cr 32% 35% 94%
Yoon et al62 vAD→vTD 55/71 51% 10% 35% 96%
richardson et al50 vrD 65/68 38% 30% 25% 100%
Berenson et al63 vAM 31/35 16% Cr 10% 13% 39%
Bensinger et al64 vCD→vTD 43/44 35% 21% 40% 96%
reeder et al65 vCD 33/33 39% 21% 27% 88%
Knop et al66 100/100 11% Cr – 68% 79
Barlogie et al67,68 vTD-PACe 480–480 – – – Nr
Abbreviations: PLD, liposomal doxorubicin; vDD, velcade, liposomal doxorubicin, dex; TD, thalidomide, dexamethasone; vTD, velcade, thalidomide, dexamethasone; vAD, vin-
cristine, adriamycin, doxorubicin;   vrD, velcade, revlimid dexamethasone;   vAM, velcade, arsenic trioxide, melphalan;   vCD, velcade, cyclophosphamide, thalidomide; vDT-PACe, 
velcade, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide.
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with its involvement in the response to many types of cellular 
stress. Human NOXA contains one BH3 (Bcl-2 homology 3) 
domain, which has a high affinity for the antiapoptotic factor 
Mcl-1. Because Mcl-1 is a target for ubiquitination, proteasome 
inhibition increases levels of Mcl-1. The induction of NOXA 
is therefore essential to override high Mcl-1 levels and allow 
for the activation of the apoptotic machinery in response to 
bortezomib.72 Also, NOXA’s interaction with anti-apoptotic 
members of the Bcl-2 family causes release of cytochrome 
c into the cytosol, leading to the activation of caspases and 
induction of apoptosis (Figure 8).73
Bortezomib induction of NOXA is also seen in melanoma 
and mantle cell lymphoma cell lines, with antisense NOXA 
oligonucleotide (but not control) resulting in a decrease in bort-
ezomib induced apoptosis.71,74 Of note, apoptosis/NOXA induc-
tion is not induced by conventional chemotherapeutic agents 
but is induced by other proteasome inhibitors (eg, MG132), 
suggesting a possible class specific effect.73,75 To understand 
why NOXA is preferentially induced in tumor cells, the myriad 
transcription factors with consensus binding sites at the NOXA 
promoter were restricted to those that are conserved (as NOXA 
itself is) across mammalian species and also dysregulated by 
proteasome inhibition and tumorogenesis. The oncogene c-myc 
emerged as a candidate mediator of tumor specificity. Indeed, 
when c-myc levels were decreased by RNA interference, 
the tumor cell-specific induction of NOXA was abrogated. 
Exogenous c-myc also increased the sensitivity of nonmalig-
nant cells to proteasome inhibition by bortezomib.72
The interaction of NOXA and c-myc also provides a 
possible rationale for the encouraging clinical data noted 
thus far when histone deacetylase (HDAC) inhibitors are 
combined with bortezomib. The transcriptional activity of 
c-myc at the NOXA promoter can be favored by chromatin 
remodeling or modification proteins (including histone acetyl 
transferases, with acetylated histone H3 being a classical 
cofactor for myc).72 HDAC inhibition is also thought to 
interfere with the targeting of ubiquinated proteins via 
the aggresome for eventual autophagy/degradation by the 
lysozome, an alternate pathway to proteasome-mediated 
degradation.76
A third possible explanation for the specificity of 
bortezomib for myeloma cells is based on the unfolded 
protein response (UPR). Plasma cells have highly developed 
rough endoplasmic reticulum (ER) and chaperone proteins 
that enable them to produce vast quantities of antibodies 
per second. If misfolded proteins accumulate in ER, the 
UPR signaling pathway is activated through its sensing 
mechanism IRE1α.77 The IRE1 kinase, in turn, results 
in the removal of an intron from the transcription factor 
XBP1, resulting in a activated ie, spliced form XBP-1.78 
Interestingly XBP-1 is is highly expressed in plasma cells 
and is a prerequisite for transformation from antigen selected 
B cell to plasma cell.
Once the UPR is activated, the unfolded proteins are 
refolded by upregulation of the chaperone molecules or 
destroyed through cytosolic 26S proteasomes; otherwise, 
accumulation of unfolded protein results in apoptosis of 
the cell (Figure 9). Proteasome inhibition triggers apoptosis 
by interfering with the UPR pathway, both at the sensing 
level as well as by preventing destruction of misfolded   
protein.79
Pathophysiology and management 
of bortezomib toxicities
Thrombocytopenia
The thrombocytopenia associated with bortezomib therapy has 
been well characterized. The platelet count drops during Days 
1 to 14 and then rapidly recovers to baseline level during Days 
15 to 21 (Figure 10). The mean reduction in relapsed/refractory 
patients is 60% and appears to be independent of the baseline 
platelet count, the concentration of the monoclonal protein, 
and bone marrow plasmacytosis. Murine studies demonstrated 
no cytotoxic effects on megakaryocytes, thus suggesting 
a mechanism distinct from traditional myelosuppressive 
chemotherapeutic agents.80
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Figure 8 Alteration in levels of Mcl-1 and NOXA results in apoptosis. Proteasome 
inhibiton increases levels of the proapoptoic factor NOXA, which then can override 
the concurrent increase in the anti-apoptic factor Mcl-1, thereby inducing the activa-
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Neuropathy
When the proteasome is inhibited, proteins accumulate in 
aggresomes at the periphery of cells and then track centrally 
via microtubules towards the microtubule-organizing center 
(MTOC).81 When the distribution of microtubules between 
polymerized and soluble fractions was compared following 
the treatment of neuroblastoma and myeloma cells with five 
proteasome inhibitors, the polymerized fraction increased 
from 41% to 68% to approximately 55% to 99%, for up 
to 144 hours after the proteasome inhibitor was removed. 
Immunofluorescence studies did not reveal microtubule 
bundles seen with taxanes, suggesting microtubule sta-
bilization occurred by a mechanism different than direct 
drug binding.82 Animal models have also found significant 
mitochondrial and endoplasmic reticulum damage in dorsal 
root ganglia.83 Other postulated mechanisms of bortezomib 
associated neuropathy include mitochondrial dysregulation 
of calcium homeostasis or dysregulation of growth factors 
important for neuron survival.84
Clinically, it is important to note the baseline rate of 
neuropathy in patients with relapsed/refractory myeloma. In 
the phase II SUMMIT and CREST studies with bortezomib, 
81% of patients had symptoms by FACT/GOG-Ntx question-
naire and 83% by neurologists’ examination.85 This likely 
reflects not only the side effects of prior treatments, but also 
a manifestation of the disease itself. While the likelihood of 
developing severe peripheral neuropathy (PN) was more fre-
quent in those patients with baseline neuropathy, the overall 
occurrence was independent of baseline neuropathy.
In the phase III APEX trial, of the 37% of patients 
who experienced peripheral neuropathy (PN), 9% had 
grade  3. The neuropathy was typically sensory, although 
2% of patients did experience motor neuropathy. The 
neuropathy does appear to be dose related with PN typically 
occurring by cycle 5 and then reaching a plateau by cycle 
8, associated with cumulative bortezomib doses of 26 and 
42 mg/m2 respectively.86 Based on similar findings in previous 
studies, the APEX trial also incorporated dose-modification 
guidelines for PN (see Table 5).
Sixty-eight percent of patients in the APEX study 
who had dose modification for grade  2 PN experienced 
improvement or resolution to baseline in their symptoms at 
a median of 110 days without any compromise in efficacy. 
The development of neuropathy was independent of age, 
prior therapies (including thalidomide and vincristine), and 
glucose intolerance/diabetes.86
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Figure 9 The unfolded protein response. if misfolded proteins accumulate in endo-
plastic reticulum, the sensing mechanism ire1α activates the transcription factor 
XBP-1 via ire1 kinase. XBP-1, in turn, activates the unfolded protein response (UPr) 
and results in apoptosis.
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A recent publication described a case series of five patients 
with myeloma who received bortezomib and then developed 
severe motor involvement. Electrophysiological evalua-
tions showed demyelinating or mixed axonal-demyelinating 
neuropathy with prominent motor involvement. Cerebrospinal 
fluid showed albumin-cytological dissociation. Importantly, 
all four patients treated with either steroids or intravenous 
immunoglobulin had improved outcomes, suggesting a 
possible immunologic cause of this neuropathy.88 Therefore, 
the development of motor neuropathy merits prompt 
neurological consultation.
Particularly in the setting of combination therapy, attenu-
ation in the dosing schedule eg, weekly treatment, appears 
to be associated with significantly less neurotoxicity. For 
example, the incidence of grade 3 or higher neuropathy with 
VMP decreased from 14% to 2% with twice weekly vs weekly 
bortezomib with preliminary outcome data showing no loss in 
efficacy.46 Interestingly, patients treated with the combination 
of the heat shock protein (HSP)-90 inhibitor tanesipmycin 
and bortezomib have not developed Grade 3 PN, suggesting 
a possible neuroprotective effect of this novel agent.89 Of note, 
development/exacerbation of PN has also not been observed 
to date with the novel proteasome inhibitor carfilzomib, 
suggesting that this may not be a class specific effect.90,91
Currently there is no proven effective prophylaxis 
for PN. A variety of agents are used for symptomatic relief 
of boretzomib associated PN including opioids, tricyclic 
antidepressants such as nortryptline, anticonvulsants such 
as gabapentin, serotonin-norepeinephrine reuptake inhibitors 
such as duloxetine, nonsteroidal anti-inflammatory agents, 
vitamins, and nutritional supplements such as α-lipoic acid, 
glutamine, and L-carnitine.84 However, with recent data 
suggesting a possible decrease in the efficacy of bortezomib 
with concomitant vitamin C92 and other supplements such as 
green tea92, neither the effectiveness in symptom palliation 
nor the absence of an interaction with bortezomib has been 
clearly established in randomized clinical trials.
The future of proteasome inhibition
A protein is first identified to be degraded by the polyubqi-
uitination of lysine residues. The process consists of sequential 
ubquitin activation, conjugation, and protein ligation – each 
catalyzed by E1, E2, and E3 enzymes (Figure 11) – which 
creates the polyubiquitination chain. It appears that there is 
a family of small ubiquitin like modifiers such as Nedd8, 
SUMO, FAT10 and ISG15 that are also able to target proteins 
for degradation.93 Each step of this process is therefore a 
putative therapeutic target. Efforts are underway to evaluate 
novel agents, with a Nedd8 activating enzyme inhibitor (MLN 
4924) already in phase I clinical trials.94
Based on the pharmacaphore that interacts with the pro-
teasome’s active site, proteasome inhibitors can be divided 
into five classes: peptide aldehydes, peptide boronotes, 
peptide vinyl sulfones, peptide epoxyketones, and the only 
nonpeptide group – β lactone inhibitors (Table 6).2 The 
peptide aldehydes such as MG-132 are the first class to be 
studied and while cell permeable, they are not only rapidly 
oxidized and unstable, but also lack specificity with activity 
against nonproteasome enzymes such as serine and cysteine 
proteases.
The peptide boronates were derived by substitution of 
the aldehyde with boron to increase potency, selectivity, and 
stability.2 Bortezomib is currently the only FDA approved 
proteasome inhibitor. Recently published preclinical data 
demonstrated activity comparable with bortezomib with 
another peptide boronate compound, CEP-18770, that is also 
water-soluble and orally bioavailable.95 Bortezomib is also 
being used as a platform for phase I/II studies with numerous 
novel agents including an anti-IL6 antibody, heat shock pro-
tein inhibitors, and epigenetic modulators such as vorinostat 
or panobinostat. These novel agents may therefore shed light 
on mechanisms of bortezomib resistance. For example, in 
two different studies, three patients who were refractory to 
bortezomib had a response to bortezomib with the addition 
of a novel agent – either tanespimycin or vorinostat.89,96
Table 6 Recommended dose modification for bortezomib-related neuropathic pain and/or peripheral sensory neuropathy87
Severity of peripheral neuropathy signs and symptoms Modification of dose and regimen
Grade I (paresthesias and/or loss of reflexes) No action
Grade i with pain or Grade 2 (interfering with function but not with  
activities of daily living)
reduce bortezomib to 1.0 mg/m2
Grade 2 with pain or Grade 3 (interfering with activities of daily living) withold bortezomib  therapy until toxicity resolves. when 
toxcicity resolves reinitiate with a reduced dose of bortezomib at 
0.7 mg/m2 and change treatment schedule to once per week
Grade 4 (disabling) Discontinue bortezomib
Grading based on NCi Common Toxicity Criteria CTCAe 3.0Biologics:   Targets & Therapy 2010:4 284
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There have been some recent developments in the 
epoxyketone class of proteasome inhibitors. Epoxomicin is 
a natural compound initially isolated from an Actinomycete 
strain and found to have antimelanoma activity in preclinical 
models.97 Carfilzomib (formerly PR-171; Proteolix®), is a 
tetrapeptide epoxyketone related to epoxomicin. There are 
two components of this agent, a peptide portion that binds to 
the substrate binding pocket(s) of the proteasome with high 
affinity and a epoxyketone pharmacophore that interacts with 
the catalytic amino-terminal threonine residue and irrevers-
ibly inhibits proteasome activity. Relative to bortezomib, 
carfilzomib more selectively inhibits the chymotrypsin-like 
activity of the proteasome with less cross-reactivity at the 
caspase-like and trypsin-like sites. At doses of 15 mg/m2 
or greater, there is 80% proteasome inhibition in both 
red blood cells and peripheral blood mononuclear cells in 
humans. The ability to give this drug safely on consecutive 
days allows for sustained proteasome inhibition.98 Preliminary 
data presented at the annual meeting of American Society of 
Hematology in 2008 from ongoing phase II studies indicate 
an overall response rate of greater than 50% and 26% in 
bortezomib-naïve91 and bortezomib-exposed90 patients with 
multiple myeloma, respectively. Cyclic thrombocytopenia 
was also noted but otherwise, the toxicity profile was different 
from bortezomib – increased creatinine and possible tumor 
lysis but no significant neuropathy.90,91,99
The first member of the β lactone class of protea-
some inhibition that received attention was derived from 
lactacystin, produced by Streptomyces. It was highly 
unstable intracellularly but was more specific than the pep-
tide aldehydes.2 Salinosporamide A (NPI-0052), a product 
of a marine actinomycete Salinispora tropica, has a bicy-
clic ring structure similar to lactacystin, but with various 
substitutions.100 Preclinical studies have shown that unlike 
bortezomib, NPI-0052 inhibits all three protease activities 
of the proteasome. It is also orally bioactive, a more potent 
inducer of apoptosis in myeloma cells than bortezomib, and 
demonstrates activity in bortezomib resistant cell lines as 
well.101 Preliminary reports from ongoing phase I studies in 
a variety of tumors indicate that the drug appears to be well   
tolerated.102–104
The development of the first-in-class proteasome inhibi-
tor bortezomib in multiple myeloma is a paradigm for the 
optimal interaction between the pharmaceutical industry, 
academic institutions, and patient advocacy groups. With 
ever increasing knowledge of the mechanism of action of 
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Table 7 Classes of proteasome inhibitors
Class Compounds
Peptide aldehydes MG132
Peptide boronates Bortezomib, CeP-18770
Peptide vinyl sulfones
Peptide epoxyketones Epoxomicin, carfilzomib
β lactone inhibitors Lactacystin, MLN 519, NPi-0052Biologics:   Targets & Therapy 2010:4 285
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this agent, the full therapeutic potential of this growing class 
of drugs can be realized.
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